Please assess the completion status of the following clinical trial:

Trial Title: Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected men and women at least 18 years of age~* On stable HAART for previous three months and without anticipated changes in their HAART regimen throughout the duration of the study~* Fasting triglycerides \> 150 mg/dl and \< 1,500 mg/dl~* Participants may be on lipid lowering therapy; if on lipid lowering therapy, therapy must be stable for 8 weeks and cannot be changes during the course of the study~* Participants may be on beta blockers (e.g., Atenolol, Metoprolol, Propranolol), Estrogens (e.g.,Estinyl;Estrace;Estraderm) and Thiazides (water pills), however therapy with these agents must be stable for 8 weeks before starting the study and cannot be altered while on the study unless deemed medically necessary by the participant's medical provider and approved by Dr. Wanke~* Female participants of reproductive age must not be pregnant (negative test) or lactating at screening and throughout the trial and agree to use 2 methods of barrier contraception for the course of the trial and 2 months after the trial unless they are surgically sterilized (tubal ligation or hysterectomy), or post-menopausal with no menses for \> 1 year~* Ability to provide consent~Exclusion Criteria:~* Plasma HIV-1 RNA \> 10,000~* Previous history of atherosclerotic disease or diabetes mellitus~* Change in HAART regimen over three months prior to study entry~* Change in lipid lowering therapy within 2 months~* On chronic anticoagulants such as heparin or coumadin~* On fish oil, omega 3 supplements, or Omacor currently or during the past month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lovaza (Type: ACTIVE_COMPARATOR): Lovaza, dietary counseling
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, dietary counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).